Osteopetrosis

Back

Background

Osteopetrosis is a clinical syndrome characterized by the failure of osteoclasts to resorb bone. As a consequence, bone modeling and remodeling are impaired. The defect in bone turnover characteristically results in skeletal fragility despite increased bone mass, and it may also cause hematopoietic insufficiency, disturbed tooth eruption, nerve entrapment syndromes, and growth impairment. (See Etiology and Presentation.)

Although human osteopetrosis is a heterogeneous disorder encompassing different molecular lesions and a range of clinical features, all forms share a single pathogenic nexus in the osteoclast.[1] Osteopetrosis was first described in 1904, by German radiologist Albers-Schönberg. (See Etiology.)[2]

Classification

In humans, 3 distinct clinical forms of the disease—infantile, intermediate, and adult onset—are identified based on age and clinical features. These variants, which are diagnosed in infancy, childhood, or adulthood, respectively, account for most cases. (See Table 1, below.)

Table 1. Clinical Classification of Human Osteopetrosis



View Table

See Table

The classification of osteopetrosis shown above is purely clinical and must be supplemented by the molecular insights gained from animal models (see Table 2, in Etiology).

Other, rare forms of osteopetrosis have been described (eg, lethal, transient, postinfectious, acquired). A distinct form of osteopetrosis occurs in association with renal tubular acidosis and cerebral calcification due to carbonic anhydrase isoenzyme II deficiency. (See Etiology.)

Epidemiology

Overall incidence of osteopetrosis is estimated to be 1 case per 100,000-500,000 population.[1, 4] However, the actual incidence is unknown, because epidemiologic studies have not been conducted.

Prognosis

In infantile osteopetrosis, bone marrow failure may occur. If untreated, infantile osteopetrosis usually results in death by the first decade of life due to severe anemia, bleeding, or infections. Patients with this condition fail to thrive, have growth retardation, and suffer increased morbidity. The prognosis of some patients with infantile osteopetrosis can markedly change after bone marrow transplantation (BMT). Patients with adult osteopetrosis have good long-term survival rates. (See Treatment and Medication.)

Patient education

Counsel patients with osteopetrosis on appropriate lifestyle modifications to prevent fractures. Provide genetic counseling to patients to allow appropriate family planning. (See Treatment.)

Etiology

To understand the etiology of osteopetrosis, understanding the bone-remodeling cycle and the cell biology of osteoclasts is essential.

Bone cells and bone modeling and remodeling

In 1999, Baron clearly and concisely reviewed the cell biology of the bone remodeling.[5] Osteoblasts synthesize bone matrix, which are composed predominantly of type I collagen and are found at the bone-forming surface. Osteoblasts are of fibroblastic origin. Extracellular matrix surrounds some osteoblasts, which become osteocytes. They are believed to play a critical role in the mechanotransduction of strain in bone remodeling.

In contrast, osteoclasts are derived from the monocyte/macrophage lineage. Osteoclasts can tightly attach to the bone matrix by integrin receptors[6] to form a sealing zone, within which is a sequestered, acidified compartment. Acidification promotes solubilization of the bone mineral in the sealing zone, and various proteases, notably cathepsin K, catalyze degradation of the matrix proteins.

Bone modeling and remodeling differ in that modeling implies a change in the shape of the overall bone and is prominent during childhood and adolescence. Modeling is the process by which the marrow cavity expands as the bone grows in diameter. Failure of modeling is the basis of hematopoietic failure in osteopetrosis. Remodeling, in contrast, involves the degradation of bone tissue from a preexisting bony structure and replacement of the degraded bone by newly synthesized bone. Failure of remodeling is the basis of the persistence of woven bone.

Osteoclast development and maturation

For precursor cells to mature, functional osteoclasts require the action of 2 distinct signals. The first is monocyte-macrophage–colony-stimulating factor (M-CSF), which is mediated by a specific membrane receptor and its signaling cascade. The second is the receptor activating NF-kappa B ligand (RANKL), acting through its cognate receptor, RANK. A soluble decoy receptor, osteoprotegerin, can bind RANKL, limiting its ability to stimulate osteoclastogenesis. In mouse models, disruption of these signaling pathways leads to an osteopetrotic phenotype.[7, 8, 9, 10]

Genetic and molecular defects in osteopetrosis

The primary underlying defect in all types of osteopetrosis is failure of the osteoclasts to reabsorb bone. A number of heterogeneous molecular or genetic defects can result in impaired osteoclastic function. The exact molecular defects or sites of these mutations largely are unknown. The defect may lie in the osteoclast lineage itself or in the mesenchymal cells that form and maintain the microenvironment required for proper osteoclast function.

The following is a review of some of the evidence suggesting disease etiology and heterogeneity of these causes:

Research has demonstrated that the clinical syndrome of adult type I osteopetrosis is not true osteopetrosis, with the increased bone mass of this condition being due to activating mutations of LRP5.[11] These mutations cause increased bone mass but no associated defect of osteoclast function. Instead, some have hypothesized that the set point of bone responsiveness to mechanical loading is altered, resulting in an altered balance between bone resorption and deposition in response to weight bearing and muscle contraction.

Some cases of type II osteopetrosis result from mutations of CLCN7, the type 7 chloride channel.[12, 13, 14] However, in other families with the clinical syndrome of type II adult osteopetrosis, linkage to other distinct genomic regions has been demonstrated. Therefore, the clinical syndrome is genetically heterogeneous.

In mice, many mutations result in osteopetrotic phenotypes (summarized in Table 2, below). Human homologs are known for only some of the murine lesions.

Table 2. Molecular Lesions Leading to Osteopetrosis in the Mouse



View Table

See Table

Osteopetrosis in carbonic anhydrase isoenzyme II deficiency

A distinct form of osteopetrosis occurs in association with renal tubular acidosis and cerebral calcification due to carbonic anhydrase isoenzyme II deficiency. This enzyme catalyzes the formation of carbonic acid from water and carbon dioxide. Carbonic acid dissociates spontaneously to release protons, which are essential for creating an acidic environment required for dissolution of bone mineral in the resorption lacunae. Lack of this enzyme results in impaired bone resorption. Clinical features vary considerably among individuals who are affected.

History and Physical Examination

Infantile osteopetrosis

Infantile osteopetrosis (also called malignant osteopetrosis) is diagnosed early in life. Failure to thrive and growth retardation are symptoms.

Bony defects and associated symptoms occur, including the following:

Adult osteopetrosis

Adult osteopetrosis (also called benign osteopetrosis) is diagnosed in late adolescence or adulthood. Two distinct types have been described, type I and type II, on the basis of radiographic, biochemical, and clinical features. (See Table 3, below.)[15]

Table 3. Types of Adult Osteopetrosis



View Table

See Table

Approximately one half of patients are asymptomatic, and the diagnosis is made incidentally; the diagnosis often made in late adolescence, because radiologic abnormalities start appearing only in childhood. In other patients, the diagnosis is based on family history. Still other patients might present with osteomyelitis or fractures.

Many patients have bone pains. Bony defects are common and include neuropathies due to cranial nerve entrapment (eg, with deafness, with facial palsy), carpal tunnel syndrome, and osteoarthritis. Bones are fragile and may fracture easily. Approximately 40% of patients have recurrent fractures. Osteomyelitis of the mandible occurs in 10% of patients.

Other manifestations include visual impairment due to retinal degeneration and psychomotor retardation. Bone marrow function is not compromised.

Physical examination

Physical findings are related to bony defects and include short stature, frontal bossing, a large head, nystagmus, hepatosplenomegaly, and genu valgum in infantile osteopetrosis.

Approach Considerations

Laboratory findings in infantile osteopetrosis include the following:

Laboratory findings in adult osteopetrosis include the following:

Genetic screening

In addition to the routine laboratory investigations listed above, mutation screening of appropriate candidate genes should be undertaken in patients whose presentation corresponds to any of the known genetic lesions. Knowledge of the molecular basis of the osteopetrosis allows clinicians to provide informed genetic counseling and, in some cases, to choose appropriate therapy.

Procedures

Bone biopsy is not essential for diagnosis, because radiographs usually are diagnostic. Histomorphometric studies of bone may be useful to predict the likelihood that BMT will succeed. Patients with crowded bone marrow are less likely than others to respond to a transplant.

Histologic findings

Failure of osteoclasts to resorb skeletal tissue is the pathognomonic feature of true osteopetrosis. Remnants of mineralized primary spongiosa are seen as islands of calcified cartilage within mature bone. Woven bone is commonly seen. Osteoclasts can be increased, normal, or decreased in number.

Histologic analysis has revealed that type I adult-onset osteopetrosis is not a genuine form of osteopetrosis, because it lacks the characteristic findings.

Radiography

Radiologic features of osteopetrosis are usually diagnostic. Because osteopetrosis encompasses a heterogeneous group of disorders, findings differ according on the variant.[17]

Patients usually have generalized osteosclerosis. Bones may be uniformly sclerotic, but alternating sclerotic and lucent bands may be noted in iliac wings and near the ends of long bones. The bones may be clublike or may have the appearance of a bone within bone (endobone). Radiographs may also show evidence of fractures or osteomyelitis.

The entire skull is thickened and dense, especially at the base. Sinuses are small and underpneumatized. Vertebrae are extremely radiodense. They may show alternating bands, known as the rugger-jersey sign (see Table 3).

Differentiating type 1 from type 2 adult osteopetrosis

Two types of adult osteopetrosis are identified on the basis of radiographs. Typing the patient's disease may be important in predicting a fracture pattern, because type II disease appears to increase the risk of fracture (see Table 3). Radiographic characteristics of type I and type II disease are as follows:

Approach Considerations

Infantile osteopetrosis

Infantile osteopetrosis warrants treatment because of the adverse outcome associated with the disease.[18] Vitamin D (calcitriol) appears to help by stimulating dormant osteoclasts, thus stimulating bone resorption. Large doses of calcitriol, along with restricted calcium intake, sometimes improve osteopetrosis dramatically.[19] However, calcitriol usually produces only modest clinical improvement, which is not sustained after therapy is discontinued.

Treatment with gamma interferon has produced long-term benefits. It improves white blood cell function, greatly decreasing the incidence of new infections. With treatment, trabecular bone volume substantially decreases and bone-marrow volume increases. This results in increases in hemoglobin, platelet counts, and survival rates. Combination therapy with calcitriol is clearly superior to calcitriol alone.

Erythropoietin can be used to correct anemia. Corticosteroids have also been used to treat anemia, as well as to stimulate bone resorption. In one study, corticosteroids resulted in a striking increase in red blood cell mass and platelet count but failed to improve bone mass. This effect on blood cells is due to reduced destruction in the reticuloendothelial system. Prednisone 1-2 mg/kg/day is usually administered for months to years. Steroids are not the preferred treatment option.

Adult osteopetrosis

Adult osteopetrosis requires no treatment by itself, although complications of the disease may require intervention. No specific medical treatment exists for the adult type.

Surgical treatment

In pediatric osteopetrosis, surgical treatment is sometimes necessary because of fractures. The constellation of problems associated with this condition and the prevailing opinions regarding their management have been reviewed.[20]

In adult osteopetrosis, surgical treatment may be needed for aesthetic reasons (eg, in patients with notable facial deformity) or for functional reasons (eg, in patients with multiple fractures, deformity, and loss of function). Severe, related degenerative joint disease may warrant surgical intervention as well.

Consultations

Refer patients to an endocrinologist with special interest and experience in bone and mineral metabolism. A patient-oriented Web site provides the names of several experts in the field.

Diet

Nutritional support is important to improve patient growth. It also enhances responsiveness to other treatment options. A calcium-deficient diet has shown some success in patients. However, patients may need calcium if hypocalcemia or rickets becomes a problem.

Bone Marrow Transplantation

BMT markedly improves some cases of infantile osteopetrosis.[21] BMT can cure bone marrow failure and metabolic abnormalities in patients whose disease arises from an intrinsic defect of the osteoclast lineage.

BMT is the only curative treatment for this disease. However, BMT may be limited to a subset of patients whose defects are extrinsic to the osteoclast lineage and whose condition is unlikely to respond. Moreover, this approach is limited, because an appropriate bone marrow donor is not always found. Also, BMT poses considerable risk because of the necessity for profound immunosuppression and the possibility of a graft-versus-host reaction. Magnetic resonance imaging (MRI) can be used to assess bones over time after BMT.

Hypercalcemia in bone marrow transplantation

Hypercalcemia can occur following hematopoietic cell transplantation (HCT), owing to the engraftment of osteoclasts arising from precursor cells. In a study of 15 patients with osteopetrosis, Martinez et al found that posttransplantation hypercalcemia developed in 40% of these individuals, occurring primarily in patients over age 2 years at the time of the HCT; the median time to onset was 23 days.[22] The hypercalcemia resolved following treatment with isotonic saline, furosemide, and subcutaneous calcitonin.

Guidelines Summary

Consensus guidelines from the Osteopetrosis Working Group give recommendations for patients with less severe forms of osteopetrosis where hematopoietic cell transplantation is not the standard treatment. The recommendations include[23] :

Medication Summary

Medications administered in osteopetrosis include the following:

Calcitriol (Rocaltrol, Calcijex, Vectical)

Clinical Context:  In large doses, with restricted calcium intake, calcitriol sometimes improves osteopetrosis dramatically. It can be used to treat infantile osteopetrosis and appears to help by stimulating dormant osteoclasts and, thus, bone resorption. Markers of bone turnover (eg, serum osteocalcin, bone-specific alkaline phosphatase, urine hydroxyproline levels) increase during therapy. However, calcitriol usually produces only modest clinical improvement, which is not sustained after discontinuation.

Class Summary

These supplements increase serum calcium levels by increasing calcium absorption from the gastrointestinal tract.

Prednisone

Clinical Context:  Prednisone is an immunosuppressant used for the treatment of autoimmune disorders. It may decrease inflammation by reversing increased capillary permeability and suppressing polymorphonuclear leukocyte activity. The drug stabilizes lysosomal membranes and suppresses lymphocytes and antibody production.

Class Summary

These agents have anti-inflammatory properties and cause profound and varied metabolic effects. Corticosteroids modify the body's immune response to diverse stimuli.

Epoetin alfa (Procrit, Epogen)

Clinical Context:  Epoetin alfa is a purified glycoprotein produced from mammalian cells modified with gene coding for human erythropoietin (EPO). The amino acid sequence is identical to that of endogenous EPO. Biological activity mimics human urinary EPO, which stimulates division and differentiation of committed erythroid progenitor cells and induces the release of reticulocytes from bone marrow into the blood stream.

Darbepoetin (Aranesp)

Clinical Context:  Darbepoetin is an erythropoiesis-stimulating protein closely related to erythropoietin, a primary growth factor produced in kidney that stimulates development of erythroid progenitor cells. Its mechanism of action is similar to that of endogenous erythropoietin, which interacts with stem cells to increase red cell production.

Darbepoetin contains 5 N-linked oligosaccharide chains, whereas epoetin alfa contains 3 such chains. Darbepoetin has longer a half-life than epoetin alfa and may be administered weekly or biweekly.

Class Summary

These agents are used to manage anemia related to chronic renal failure, rheumatoid arthritis, and AIDS.

Gamma-1b interferon (Actimmune)

Clinical Context:  Gamma-1b interferon is synthesized by eukaryotic cells in response to viruses and a variety of natural and synthetic stimuli. It possesses antiviral, immunomodulatory, and antiproliferative activity. Gamma interferon has potent phagocyte-activating effects not seen with other interferon preparations. It works by stimulating osteoclast activity.

Class Summary

These agents delay disease progression in severe, malignant osteopetrosis.[24] Combined with calcitriol, interferons are substantially more effective than calcitriol alone. The combination reduces the incidence of severe infections, the number of transfusions needed, and the patient’s bone mass considerably more than calcitriol alone. The FDA approved interferon in 2000 for use in children with osteopetrosis.

Author

Robert Blank, MD, PhD, Professor of Medicine, Cell Biology, and Physiology, Chief, Division of Endocrinology, Metabolism, and Clinical Nutrition, Director, TOPS Obesity Center, Medical College of Wisconsin; Staff Physician, Clement J Zablocki Veterans Affairs Medical Center

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Bristol-Myers Squibb.

Coauthor(s)

Anuj Bhargava, MD, MBA, Adjunct Assistant Professor, Drake College of Pharmacy; Co-Director, Diabetes Institute, Mercy Medical Center; President, Iowa Diabetes and Endocrinology Research Center; President, My Diabetes Home, LLC

Disclosure: Received honoraria from Merck for speaking, research trials; Received honoraria from Novo Nordisk for speaking and teaching; Received honoraria from Sanofi for speaking and teaching; Received honoraria from takeda for speaking and teaching; Received honoraria from Abbott for speaking and teaching; Received grant/research funds from Lilly for research trials; Received grant/research funds from Gilead for research trials; Received grant/research funds from Novartis for research trials; Received gr.

Chief Editor

George T Griffing, MD, Professor Emeritus of Medicine, St Louis University School of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

Romesh Khardori, MD, PhD, FACP Former Professor, Department of Medicine, Former Chief, Division of Endocrinology, Metabolism, and Molecular Medicine, Southern Illinois University School of Medicine

Romesh Khardori, MD, PhD, FACP is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians, American Diabetes Association, and Endocrine Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Stanley Wallach, MD Executive Director, American College of Nutrition; Clinical Professor, Department of Medicine, New York University School of Medicine

Stanley Wallach, MD is a member of the following medical societies: American College of Nutrition, American Society for Bone and Mineral Research, American Society for Clinical Investigation, American Society for Clinical Nutrition, American Society for Nutritional Sciences, Association of American Physicians, and Endocrine Society

Disclosure: Nothing to disclose.

References

  1. Stark Z, Savarirayan R. Osteopetrosis. Orphanet J Rare Dis. 2009 Feb 20. 4:5. [View Abstract]
  2. Albers-Schonberg H. Roentgenbilder einer seltenen Knochennerkrankung. Munch Med Wochenschr. 1904. 51:365.
  3. van Hove RP, de Jong T, Nolte PA. Autosomal dominant type I osteopetrosis is related with iatrogenic fractures in arthroplasty. Clin Orthop Surg. 2014 Dec. 6(4):484-8. [View Abstract]
  4. Beighton P, Hamersma H, Cremin BJ. Osteopetrosis in South Africa. The benign, lethal and intermediate forms. S Afr Med J. 1979 Apr 21. 55(17):659-65. [View Abstract]
  5. Baron R. Anatomy and Ultrastructure of Bone. Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th ed. Philadelphia, Pa: Lippincott, Williams, and Wilkins; 1999. 3-10.
  6. Plow EF, Qin J, Byzova T. Kindling the flame of integrin activation and function with kindlins. Curr Opin Hematol. 2009 Sep. 16(5):323-8. [View Abstract]
  7. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000 Sep 1. 289(5484):1504-8. [View Abstract]
  8. Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med. 2004 Dec 30. 351(27):2839-49. [View Abstract]
  9. Wada T, Nakashima T, Oliveira-dos-Santos AJ, et al. The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat Med. 2005 Apr. 11(4):394-9. [View Abstract]
  10. Pangrazio A, Cassani B, Guerrini MM, Crockett JC, Marrella V, Zammataro L, et al. RANK-dependent autosomal recessive osteopetrosis: characterisation of 5 new cases with novel mutations. J Bone Miner Res. 2011 Nov 9. [View Abstract]
  11. Van Wesenbeeck L, Cleiren E, Gram J, et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet. 2003 Mar. 72(3):763-71. [View Abstract]
  12. Cleiren E, Benichou O, Van Hul E, et al. Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet. 2001 Dec 1. 10(25):2861-7. [View Abstract]
  13. Kornak U, Kasper D, Bosl MR, et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell. 2001 Jan 26. 104(2):205-15. [View Abstract]
  14. Bonapace G, Moricca M, Talarico V, Graziano F, Pensabene L, Miniero R. Identification of two novel mutations on CLCN7 gene in a patient with malignant ostopetrosis. Ital J Pediatr. 2014 Nov 20. 40(1):90. [View Abstract]
  15. el-Tawil T, Stoker DJ. Benign osteopetrosis: a review of 42 cases showing two different patterns. Skeletal Radiol. 1993 Nov. 22(8):587-93. [View Abstract]
  16. Matar HE, James LA. A challenging paediatric pathological femur fracture in pyknodysostosis (osteopetrosis acro-osteolytica): lessons learnt. BMJ Case Rep. 2014 Nov 20. 2014:[View Abstract]
  17. Fotiadou A, Arvaniti M, Kiriakou V, et al. Type II autosomal dominant osteopetrosis: radiological features in two families containing five members with asymptomatic and uncomplicated disease. Skeletal Radiol. 2009 Oct. 38(10):1015-21. [View Abstract]
  18. Symposium on Osteopetrosis. Proceedings and abstracts of the First International Symposium on Osteopetrosis: biology and therapy. October 23-24, 2003. Bethesda, Maryland, USA. J Bone Miner Res. 2004 Aug. 19(8):1356-75. [View Abstract]
  19. Key L, Carnes D, Cole S, et al. Treatment of congenital osteopetrosis with high-dose calcitriol. N Engl J Med. 1984 Feb 16. 310(7):409-15. [View Abstract]
  20. Armstrong DG, Newfield JT, Gillespie R. Orthopedic management of osteopetrosis: results of a survey and review of the literature. J Pediatr Orthop. 1999 Jan-Feb. 19(1):122-32. [View Abstract]
  21. Mazzolari E, Forino C, Razza A, et al. A single-center experience in 20 patients with infantile malignant osteopetrosis. Am J Hematol. 2009 Aug. 84(8):473-9. [View Abstract]
  22. Martinez C, Polgreen LE, Defor TE, et al. Characterization and management of hypercalcemia following transplantation for osteopetrosis. Bone Marrow Transplant. 2009 Oct 5. [View Abstract]
  23. Wu CC, Econs MJ, DiMeglio LA, Insogna KL, Levine MA, Orchard PJ, et al. Diagnosis and Management of Osteopetrosis: Consensus Guidelines from the Osteopetrosis Working Group. J Clin Endocrinol Metab. 2017 Jun 26. [View Abstract]
  24. Key LL Jr, Rodriguiz RM, Willi SM, et al. Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med. 1995 Jun 15. 332(24):1594-9. [View Abstract]
  25. Croke M, Ross FP, Korhonen M, Williams DA, Zou W, Teitelbaum SL. Rac deletion in osteoclasts causes severe osteopetrosis. J Cell Sci. 2011 Nov 15. 124:3811-21. [View Abstract]
Characteristic Adult onset Infantile Intermediate
InheritanceAutosomal dominant[3] Autosomal recessiveAutosomal recessive
Bone marrow failureNoneSevereNone
PrognosisGoodPoorPoor
DiagnosisOften diagnosed incidentallyUsually diagnosed before age 1yNot applicable
Gene Protein Lesion Phenotype Human Equivalent Key References
Csf1 M-CSFNaturally occurring op allele (frame shift)Reduced size, short limbs, domed skull, absence of teeth, poor hearing, poor fertility, extramedullary hematopoiesis, rescued by administration of M-CSFNone knownYoshida et al, 1990
Csf1r M-CSF receptorTargeted disruption in exon 3Reduced size, short limbs, domed skull, absence of teeth, poor fertility, extramedullary hematopoiesis, slightly more severe than Csf1opphenotypeNone knownDai et al, 2002
Tnfsf11 RANKLTargeted disruptionsOsteopetrosis, failure of lymph nodes to developNone knownKong et al, 1999; Kim et al, 2000
Tnfrsf11a RANKTargeted disruptionsOsteopetrosis, failure of lymph nodes to developDuplications in exon 1 found in Paget disease and in familial expansile osteolysisLi et al, 2000
Ostm1 Osteopetrosis-associated transmembrane protein 1Naturally occurring deletionAbnormal coat color, short lifespan, chondrodysplasia, failure of tooth eruption, osteopetrosisInfantile malignant osteopetrosisChalhoub et al, 2003
Acp5 Tartrate resistant acid phosphatase (acid phosphatase 5)Targeted disruptionChondrodysplasia, osteopetrosisNone knownHayman et al, 1996
Car2 Carbonic anhydrase IIN -ethyl-N -nitrosourea (ENU) mutagenesisNo skeletal phenotype in mouse, renal tubular acidosis, growth retardationOsteopetrosis with renal tubular acidosisLewis et al, 1988
Clcn7 Chloride channel 7Targeted disruptionsChondrodysplasia, osteopetrosis, failure of tooth eruption, optic atrophy, retinal degeneration, premature deathAutosomal dominant type 2 osteopetrosis, autosomal recessive osteopetrosisKornak et al, 2001; Cleiren et al, 2001
Ctsk Cathepsin KTargeted disruptionOsteopetrosis with increased osteoclast surfacePycnodysostosisSaftig et al, 1998; Kiviranta et al, 2005
Gab2 Grb2 -associated binder 2Targeted disruptionOsteopetrosis, defective osteoclast maturationNone knownWada et al, 2005
Mitf Micro-ophthalmia–associated transcription factorSpontaneous mutations, ENU mutagenesis, radiation mutagenesis, targeted disruption, untargeted insertional mutagenesisPigmentation failure, failure of tooth eruption, osteopetrosis, microphthalmia, infertility in both sexesWaardenburg syndrome, type 2a; Tietz syndrome, ocular albinism with sensorineural deafnessHodgkinson et al, 1993; Steingrimsson et al, 1994
Src c-SRCTargeted disruptionOsteopetrosis, failure of tooth eruption, premature death, reduced body size, female infertility, poor nursingNone knownSoriano et al, 1991
Tcirg1 116-kD subunit of vacuolar proton pumpSpontaneous deletion, targeted disruptionOsteopetrosis, failure of tooth eruption, chondrodysplasia, small size, premature deathAutosomal recessive osteopetrosisLi et al, 1999; Scimeca et al, 2000; Frattini et al, 2000
Traf6 Tumor necrosis factor (TNF)-receptor–associated factor 6Targeted disruptionsOsteopetrosis, failure of tooth eruption, decreased body size, premature death, impaired maturation of dendritic cellsNone knownNaito et al, 1999; Lomaga et al, 1999; Kobayashi et al, 2003
Characteristic Type I Type II
Skull sclerosisMarked sclerosis mainly of the vaultSclerosis mainly of the base
SpineDoes not show much sclerosisShows the rugger-jersey appearance
PelvisNo endobonesShows endobones in the pelvis
Transverse banding of metaphysisAbsentMay or may not be present
Risk of fractureLowHigh
Serum acid phosphataseNormalVery high